Fundamental Analysis of Aslan Pharmaceuticals Ltd ADR - Growth / Value Index
ASLN - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Book Value in last 3 years is trending down
Book value is negative
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -1.41 | -0.162 | 73.18 % | |
| Price to Book | -24.32 | -42.43 | -1246.91 % | -0.577 |
| Price to Sales | 4.54 | 0.608 | -76.41 % | |
| Enterprise Value to EBITDA Multiple | -0.451 | -0.313 | -27.01 % |
ASLN - Profitability Highlights
Profitability Analysis
Excellent QoQ /QoQ FY EPS growth
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
EPS decline for last four quarters
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 0 | 0 | 0 % | 0 |
| Return On Asset | -92.21 | -183.49 | -118.50 % | -54.87 |
| Net Profit Margin | -321.83 | -376.57 | 12.06 % | 0 |
| Operating Profit Margin | -320.04 | -366.71 | 7.56 % | 0 |
| EBITDA Margin | -288.46 | -342.30 | 13.11 % | 0 |
Highlights
| Market Cap | 10039.51 K |
| Enterprise Value | 15612.58 K |
| Price/Book TTM | -24.32 |
| Outstanding Share | 22626.80 K |
| Float/ Outstanding Share | 2157.40% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 6.00 |
| Altman Z Score | -22.54 |
| Sloan Ratio | -2.06 |
| Peter Lynch Fair Value | 0 |
ASLN - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Very Poor Score of 5.00
Quarterly sales in last 5 Quarter is trending down
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 12000.00 K | 0 % | % |
| Gross Profit | 12000.00 K | 3612.11 % | % |
| EBITDA | -34615.70 K | 13.11 % | 2.61 % |
| Net Profit | -38619.70 K | 12.06 % | 0 % |
| EPS | -0.315 | 272.88 % | NA |
ASLN - Stability Highlights
Stability Analysis
Debt to equity ratio has decreased and is lowest in last three years
Tsr Stability Index - Very Poor Score of 6.25
Altman Z Score of -22.56 suggest high risk
Interest Coverage of -10.07
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | -2.02 | -144.89 % | -1.61 |
| Cash Ratio | 1.62 | -34.03 % | |
| Quick Ratio | 0 | 0 % | 1.84 |
| Shareholders Equity | -53.95 | -494.63 % | |
| Debt to EBITDA | -0.653 | 17.93 % |
Historical Valuation Ratios of Aslan Pharmaceuticals Ltd ADR
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Aslan Pharmaceuticals Ltd ADR
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Aslan Pharmaceuticals Ltd ADR
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Aslan Pharmaceuticals Ltd ADR
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)